Press-release for stocks for AGNPF

Prices are updated after-hours

symbols : AGNPF source : Www.globenewswire.com

save search

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -4.62% | O: 11.33% H: 0.0% C: -23.62%
ceo pharmaceuticals

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -16.83% | O: 0.37% H: 4.5% C: -11.69%
drug stroke pharmaceuticals research program

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2024-03-27 (Crawled : 16:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| 10.0% | O: 25.81% H: 0.0% C: 0.0%
acquisition pharmaceuticals research program

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Published: 2024-01-31 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| 14.05% | O: 5.02% H: 13.06% C: 11.46%
patent treat pharmaceuticals grant chinese

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
Published: 2024-01-11 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| Email alert Add to watchlist
patent japan fibrosis pharmaceuticals

Algernon Pharmaceuticals Announces Closing of Private Placement
Published: 2023-12-27 (Crawled : 21:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| 36.4% | O: 9.2% H: 20.51% C: 15.38%
pharmaceuticals

Algernon Pharmaceuticals Announces Increase to Private Placement
Published: 2023-12-27 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| 36.4% | O: 0.0% H: 0.0% C: 0.0%
pharmaceuticals

Algernon Pharmaceuticals Announces Private Placement
Published: 2023-12-13 (Crawled : 01:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| 19.65% | O: 3.68% H: 0.0% C: -5.92%
pharmaceuticals

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2023-11-22 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| 29.17% | O: 7.95% H: 45.61% C: 24.56%
acquisition pharmaceuticals research program

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| 31.15% | O: -8.27% H: 0.0% C: 0.0%
patent treatment pharmaceuticals nash

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -39.38% | O: 11.11% H: 1.6% C: -4.24%
patent pharmaceuticals grant nash

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -51.56% | O: -7.67% H: 0.0% C: 0.0%
drug stroke study phase 2

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
Published: 2023-07-14 (Crawled : 22:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| Email alert Add to watchlist
pharmaceuticals financial agreement

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -53.0% | O: 3.1% H: 0.94% C: -3.21%
drug group pharmaceuticals program phase 2

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
Published: 2023-06-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -58.92% | O: 8.43% H: 2.28% C: 2.28%
conference pharmaceuticals phase 2

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
Published: 2023-06-05 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -63.14% | O: 0.0% H: 1.14% C: -10.27%
stroke

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
Published: 2023-05-31 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -57.21% | O: -4.89% H: 0.0% C: 0.0%
patent treatment pharmaceuticals

Algernon Pharmaceuticals Announces Closing of Rights Offering
Published: 2023-05-05 (Crawled : 21:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| Email alert Add to watchlist
offering pharmaceuticals

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
Published: 2023-03-02 (Crawled : 13:20) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -94.37% | O: -0.93% H: 0.0% C: -5.83%
care global neurological

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split
Published: 2023-03-01 (Crawled : 02:00) - globenewswire.com
AGNPF | $0.0682 178.69% 300

Health Technology

| -94.54% | O: -4.8% H: 5.88% C: 1.79%
pharmaceuticals